-
1دورية أكاديمية
المؤلفون: Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang Yao
المصدر: Frontiers in Oncology, Vol 12 (2022)
مصطلحات موضوعية: osteosarcoma, chondrosarcoma, multitarget tyrosine kinase inhibitor, angiogenesis, anlotinib, progress-free survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2022.811687/fullTest; https://doaj.org/toc/2234-943XTest
-
2
المؤلفون: Wenhao Niu, Hao Pan, Qiang Wang
المصدر: Acta Neurochirurgica
مصطلحات موضوعية: Adult, medicine.medical_specialty, Indoles, Receptor, Platelet-Derived Growth Factor alpha, Neurology, medicine.drug_class, medicine.medical_treatment, Case Report - Tumor - Glioma, Anlotinib, Tyrosine-kinase inhibitor, Targeted therapy, Histones, Glioma, Humans, Medicine, Molecular Targeted Therapy, Neuroradiology, medicine.diagnostic_test, Brain Neoplasms, business.industry, Diffuse midline gliomas, Interventional radiology, Protein-Tyrosine Kinases, medicine.disease, H3K27M mutation, Mutation, Mutation (genetic algorithm), Quinolines, Cancer research, Multitarget tyrosine kinase inhibitor, Surgery, Neurology (clinical), Neurosurgery, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c56f1538053fcf00c899408021debcc9Test
http://europepmc.org/articles/PMC8609840Test -
3دورية أكاديمية
المؤلفون: Ielasi L., Tovoli F., Piscaglia F.
المساهمون: Ielasi L., Tovoli F., Piscaglia F.
مصطلحات موضوعية: Hepatocellular carcinoma, Lenvatinib, Liver cancer therapy, Multitarget tyrosine kinase inhibitor, Oncolytic drug, Antineoplastic Agent, Carcinoma, Hepatocellular, Clinical Trials, Phase III as Topic, Human, Liver Neoplasm, Mesylate, Phenylurea Compound, Quinoline, Randomized Controlled Trials as Topic
وصف الملف: ELETTRONICO
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31131841; info:eu-repo/semantics/altIdentifier/wos/WOS:000468507700002; volume:55; issue:5; firstpage:305; lastpage:313; numberofpages:9; journal:DRUGS OF TODAY; http://hdl.handle.net/11585/714926Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85066507812; https://journals.prous.com/journals/servlet/xmlxsl/dot/20195505/pdf/dt550305.pdf?p_JournalId=4&p_refId=2969817&p_IsPs=NTest
الإتاحة: https://doi.org/10.1358/dot.2019.55.5.2969817Test
http://hdl.handle.net/11585/714926Test
https://journals.prous.com/journals/servlet/xmlxsl/dot/20195505/pdf/dt550305.pdf?p_JournalId=4&p_refId=2969817&p_IsPs=NTest -
4
المؤلفون: Fabio Piscaglia, Francesco Tovoli, Luca Ielasi
المساهمون: Ielasi L., Tovoli F., Piscaglia F.
المصدر: Drugs of today (Barcelona, Spain : 1998). 55(5)
مصطلحات موضوعية: Oncology, Sorafenib, Phenylurea Compound, medicine.medical_specialty, Carcinoma, Hepatocellular, medicine.drug_class, Hepatocellular carcinoma, Quinoline, Antineoplastic Agents, Liver cancer therapy, Placebo, 030226 pharmacology & pharmacy, Tyrosine-kinase inhibitor, Antineoplastic Agent, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Carcinoma, Mesylate, Lenvatinib, Humans, Lenvatinib Mesylate, neoplasms, Randomized Controlled Trials as Topic, Mesylates, business.industry, Phenylurea Compounds, Liver Neoplasms, Oncolytic drug, medicine.disease, digestive system diseases, Clinical trial, chemistry, Clinical Trials, Phase III as Topic, Liver Neoplasm, Multitarget tyrosine kinase inhibitor, Quinolines, business, medicine.drug, Human
وصف الملف: ELETTRONICO
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4e91fb81b6dfd6ba64c9d4a19d1aab3Test
https://pubmed.ncbi.nlm.nih.gov/31131841Test